Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective

Juliana C.N. Chan, Chaicharn Deerochanawong, A. Samad Shera, Kun Ho Yoon, John M.F. Adam, Ta Van Binh, Siew Pheng Chan, Richard Elwyn Fernando, Lee Chung Horn, Nguyen Thy Khue, Augusto D. Litonjua, Sidartawan Soegondo, Paul Zimmet

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Increases in the prevalence of type 2 diabetes of 30-60% will occur in many Asian-Pacific countries by 2025, driven by urbanisation, sedentary habits and energy-rich diets. Obesity, insulin resistance, metabolic syndrome and diabetes are closely interrelated. Optimal control of diabetes and associated risk factors has reduced the risk of diabetes-related complications. In the UK Prospective Diabetes Study (UKPDS), metformin reduced the risk of macrovascular complications and retrospective analyses have confirmed the efficacy of metformin in improving clinical outcomes in type 2 diabetic patients with a history of cardiovascular disease. This growing body of evidence has led to the recommendation of metformin as optimum initial pharmacotherapy in overweight type 2 diabetic patients. Obesity is less prevalent in the Asian-Pacific population than in Caucasian populations. Nevertheless, metformin has multiple beneficial metabolic effects, which provide sufficient rationale for it to be recommended as the initial oral anti-diabetic pharmacotherapy, alone or in combination, irrespective of body mass index. This recommendation is consistent with global guidelines and regional recommendations for the Asian-Pacific region from the International Diabetes Federation. These recommendations can serve as templates for development of local guidelines for Asian people with diabetes, given the ethnic and cultural diversity within the region.

LanguageEnglish
Pages255-266
Number of pages12
JournalDiabetes Research and Clinical Practice
Volume75
Issue number3
DOIs
Publication statusPublished - 1 Mar 2007

Keywords

  • Asian-Pacific
  • Glycaemia
  • Metformin
  • Oral anti-diabetic agents
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Chan, J. C. N., Deerochanawong, C., Shera, A. S., Yoon, K. H., Adam, J. M. F., Van Binh, T., ... Zimmet, P. (2007). Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective. Diabetes Research and Clinical Practice, 75(3), 255-266. https://doi.org/10.1016/j.diabres.2006.06.023
Chan, Juliana C.N. ; Deerochanawong, Chaicharn ; Shera, A. Samad ; Yoon, Kun Ho ; Adam, John M.F. ; Van Binh, Ta ; Chan, Siew Pheng ; Fernando, Richard Elwyn ; Horn, Lee Chung ; Khue, Nguyen Thy ; Litonjua, Augusto D. ; Soegondo, Sidartawan ; Zimmet, Paul. / Role of metformin in the initiation of pharmacotherapy for type 2 diabetes : An Asian-Pacific perspective. In: Diabetes Research and Clinical Practice. 2007 ; Vol. 75, No. 3. pp. 255-266.
@article{9b8b081df3f24aeab6a0f27abac127c9,
title = "Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective",
abstract = "Increases in the prevalence of type 2 diabetes of 30-60{\%} will occur in many Asian-Pacific countries by 2025, driven by urbanisation, sedentary habits and energy-rich diets. Obesity, insulin resistance, metabolic syndrome and diabetes are closely interrelated. Optimal control of diabetes and associated risk factors has reduced the risk of diabetes-related complications. In the UK Prospective Diabetes Study (UKPDS), metformin reduced the risk of macrovascular complications and retrospective analyses have confirmed the efficacy of metformin in improving clinical outcomes in type 2 diabetic patients with a history of cardiovascular disease. This growing body of evidence has led to the recommendation of metformin as optimum initial pharmacotherapy in overweight type 2 diabetic patients. Obesity is less prevalent in the Asian-Pacific population than in Caucasian populations. Nevertheless, metformin has multiple beneficial metabolic effects, which provide sufficient rationale for it to be recommended as the initial oral anti-diabetic pharmacotherapy, alone or in combination, irrespective of body mass index. This recommendation is consistent with global guidelines and regional recommendations for the Asian-Pacific region from the International Diabetes Federation. These recommendations can serve as templates for development of local guidelines for Asian people with diabetes, given the ethnic and cultural diversity within the region.",
keywords = "Asian-Pacific, Glycaemia, Metformin, Oral anti-diabetic agents, type 2 diabetes",
author = "Chan, {Juliana C.N.} and Chaicharn Deerochanawong and Shera, {A. Samad} and Yoon, {Kun Ho} and Adam, {John M.F.} and {Van Binh}, Ta and Chan, {Siew Pheng} and Fernando, {Richard Elwyn} and Horn, {Lee Chung} and Khue, {Nguyen Thy} and Litonjua, {Augusto D.} and Sidartawan Soegondo and Paul Zimmet",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.diabres.2006.06.023",
language = "English",
volume = "75",
pages = "255--266",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Chan, JCN, Deerochanawong, C, Shera, AS, Yoon, KH, Adam, JMF, Van Binh, T, Chan, SP, Fernando, RE, Horn, LC, Khue, NT, Litonjua, AD, Soegondo, S & Zimmet, P 2007, 'Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective', Diabetes Research and Clinical Practice, vol. 75, no. 3, pp. 255-266. https://doi.org/10.1016/j.diabres.2006.06.023

Role of metformin in the initiation of pharmacotherapy for type 2 diabetes : An Asian-Pacific perspective. / Chan, Juliana C.N.; Deerochanawong, Chaicharn; Shera, A. Samad; Yoon, Kun Ho; Adam, John M.F.; Van Binh, Ta; Chan, Siew Pheng; Fernando, Richard Elwyn; Horn, Lee Chung; Khue, Nguyen Thy; Litonjua, Augusto D.; Soegondo, Sidartawan; Zimmet, Paul.

In: Diabetes Research and Clinical Practice, Vol. 75, No. 3, 01.03.2007, p. 255-266.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Role of metformin in the initiation of pharmacotherapy for type 2 diabetes

T2 - Diabetes Research and Clinical Practice

AU - Chan, Juliana C.N.

AU - Deerochanawong, Chaicharn

AU - Shera, A. Samad

AU - Yoon, Kun Ho

AU - Adam, John M.F.

AU - Van Binh, Ta

AU - Chan, Siew Pheng

AU - Fernando, Richard Elwyn

AU - Horn, Lee Chung

AU - Khue, Nguyen Thy

AU - Litonjua, Augusto D.

AU - Soegondo, Sidartawan

AU - Zimmet, Paul

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Increases in the prevalence of type 2 diabetes of 30-60% will occur in many Asian-Pacific countries by 2025, driven by urbanisation, sedentary habits and energy-rich diets. Obesity, insulin resistance, metabolic syndrome and diabetes are closely interrelated. Optimal control of diabetes and associated risk factors has reduced the risk of diabetes-related complications. In the UK Prospective Diabetes Study (UKPDS), metformin reduced the risk of macrovascular complications and retrospective analyses have confirmed the efficacy of metformin in improving clinical outcomes in type 2 diabetic patients with a history of cardiovascular disease. This growing body of evidence has led to the recommendation of metformin as optimum initial pharmacotherapy in overweight type 2 diabetic patients. Obesity is less prevalent in the Asian-Pacific population than in Caucasian populations. Nevertheless, metformin has multiple beneficial metabolic effects, which provide sufficient rationale for it to be recommended as the initial oral anti-diabetic pharmacotherapy, alone or in combination, irrespective of body mass index. This recommendation is consistent with global guidelines and regional recommendations for the Asian-Pacific region from the International Diabetes Federation. These recommendations can serve as templates for development of local guidelines for Asian people with diabetes, given the ethnic and cultural diversity within the region.

AB - Increases in the prevalence of type 2 diabetes of 30-60% will occur in many Asian-Pacific countries by 2025, driven by urbanisation, sedentary habits and energy-rich diets. Obesity, insulin resistance, metabolic syndrome and diabetes are closely interrelated. Optimal control of diabetes and associated risk factors has reduced the risk of diabetes-related complications. In the UK Prospective Diabetes Study (UKPDS), metformin reduced the risk of macrovascular complications and retrospective analyses have confirmed the efficacy of metformin in improving clinical outcomes in type 2 diabetic patients with a history of cardiovascular disease. This growing body of evidence has led to the recommendation of metformin as optimum initial pharmacotherapy in overweight type 2 diabetic patients. Obesity is less prevalent in the Asian-Pacific population than in Caucasian populations. Nevertheless, metformin has multiple beneficial metabolic effects, which provide sufficient rationale for it to be recommended as the initial oral anti-diabetic pharmacotherapy, alone or in combination, irrespective of body mass index. This recommendation is consistent with global guidelines and regional recommendations for the Asian-Pacific region from the International Diabetes Federation. These recommendations can serve as templates for development of local guidelines for Asian people with diabetes, given the ethnic and cultural diversity within the region.

KW - Asian-Pacific

KW - Glycaemia

KW - Metformin

KW - Oral anti-diabetic agents

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33846258421&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2006.06.023

DO - 10.1016/j.diabres.2006.06.023

M3 - Review article

VL - 75

SP - 255

EP - 266

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -